Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Atezolizumab in Advanced Liver Cancer With MASLD
NCT07285850Phase 3Recruiting
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Oct 2025
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab, atezolizumab in hepatocellular carcinoma (HCC), sponsored by Eastern Hepatobiliary Surgery Hospital. Started Oct 2025; status: recruiting.
02
Drugs
bevacizumabatezolizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07285850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07285850.